Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
Seggewiss-Bernhardt R et al. Cancer. 2015 Mar 24. doi: 10.1002/cncr.29339. [Epub ahead of print].

O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies.
Herait P et al. Ann Oncol. 2015 Mar;26 Suppl 2:ii10. doi: 10.1093/annonc/mdv085.3.

Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.
Ocio EM et al. Haematologica. 2015 Mar 20. pii: haematol.2015.124164. [Epub ahead of print].

Phase I/II study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.
Moreau P et al. Blood. 2015 Mar 17. pii: blood-2015-02-626168. [Epub ahead of print].

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström’s Macroglobulinemia.
Kuiatse I et al. Clin Cancer Res. 2015 Mar 6. pii: clincanres.1462.2014. [Epub ahead of print].